ArticleBMC musculoskeletal disorders2025
Ultrasound-guided injection of platelet-rich plasma alleviated pain and improved function for individuals with myofascial pain syndrome: a retrospective case series study.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions.Biomedicines · 2026Article
- Myofascial pain in older adults: a geroscience-informed framework integrating precision geriatrics and digital therapeutics.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMyofascial pain syndrome (MPS) is a regional musculoskeletal pain associated with myofascial trigger point (MTrP), lacks therapies with sustained efficacy. Current modalities offer short-term relief but fail to address underlying tissue degeneration.
objectivesThis study aimed to evaluate the 3-month safety and efficacy of ultrasound-guided platelet-rich plasma (PRP) injections in alleviating MPS-related pain and function.
methodsFrom January 2023 to April 2023, we selected 71 eligible individuals with MPS who received PRP treatment of the upper trapezius, rhomboid, erector spinae, and quadratus lumborum in the Department of Rehabilitation Medicine, West China Hospital, Sichuan University, a retrospective case series study. Primary outcome was pain quantified by the Visual Analog Scale (VAS) and the McGill Pain Questionnaire (McGill). Secondary outcomes were region-specific functional improvement evaluated using the Neck Disability Index (NDI) for cervical pathology and the Oswestry Disability Index (ODI) for lumbar conditions, with additional assessment via the Roland Morris Disability Questionnaire (RMDQ), and quality of life measured by the Medical Outcomes Short Form-36 (SF-36). These parameters were evaluated at baseline and 24 h, 2 weeks, 1 month, and 3 months post-treatment.
resultsThe cohort included 71 individuals (mean age 47.6 ± 15.9 years; 71.8% female) with chronic MPS. The pain VAS decreased from 5.0 [4.0-6.0] at baseline to 1.0 [1.0-2.0] at 3 months (p < 0.001), with the McGill decreased from 11.0 [8.0-15.0] to 2.0 [2.0-5.0] (p < 0.001). The NDI decreased from 42.0 [29.3-53.3] at baseline to 9.5 [5.0-11.0] (p < 0.001). The ODI declined from 22.0 [14.0-29.0] to 10.0 [6.0-14.0] (p < 0.001). The RMDQ showed improvement, from 10.0 [6.5-16.0] to 4.0 [2.0-5.0] (p < 0.001). Similarly, the SF-36 score was obviously improved 3 months post-treatment of PRP (p < 0.01). No adverse reactions were reported during follow-up.
conclusionUltrasound-guided platelet-rich plasma treatment could significantly alleviate the pain and improve the physical function and quality of life in the individuals with myofascial pain syndrome during 3-months follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.